Anistreplase
Top View
- Endovascular Pharmacology Chart
- Division of Vital Statistics, Mortality Data Table Page 1 of 147
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- 1216 Cardiovascular Drugs Preparations 90 Minutes
- Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting
- Drug Fee Schedule
- A Critical Review of the Efficacy and Safety in the Use of Low-Molecular-Weight Heparin in Acute ST-Elevation Myocardial Infarction: a Bayesan Approach
- A Systemic Non-Lytic State and Localthrombolytic
- Watch out for Indirect Comparisons!
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Anistreplase Versus Alteplase in Acute Myocardial Infarction: Comparative Effects on Left Ventricular Function, Morbidity and L-Day Coronary Artery Patency
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- Thrombin Generation and Activity During Thrombolysis and Concomitant Heparin Therapy in Patients with Acute Myocardial Infarction
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Antithrombotic Therapy in Patients with Acute Coronary Syndromes
- HRAG Instructions (Qxqs) This Table Summarizes Changes to the HRA Qxq As of 10/11/2019 Question in HRA
- Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
- Monitoring of Streptokinase Resistance Titre in Acute Myocardial Infarction